Oppenheimer Assumes Seres Therapeutics at Outperform, Announces Price Target of $12
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Mark Breidenbach assumes Seres Therapeutics (NASDAQ:MCRB) with an Outperform rating and announces a price target of $12.
June 26, 2023 | 10:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Seres Therapeutics receives an Outperform rating from Oppenheimer analyst Mark Breidenbach, with a price target of $12.
The Outperform rating from Oppenheimer analyst Mark Breidenbach indicates a positive outlook for Seres Therapeutics' stock price in the short term. The price target of $12 suggests potential upside, which could attract investors and drive the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100